Is there more internal financing or external financing for Xiangxue Pharmaceutical?

There are many outside. Xiangxue Pharmaceutical completed 500 million yuan Series A financing, which was led by Haitong Innovation; Xiangxue Pharmaceutical received10.50 billion yuan in Series B financing, which was led by SDIC Venture Capital; Xiangxue Pharmaceutical completed the 300 million yuan Series C financing, which was led by Fosun Pharma; Xiangxue Pharmaceutical announced the completion of 65.438 billion yuan D round of financing, led by Sequoia Capital China and Huaying Capital; Xiangxue Pharmaceutical received 654.38+0.5 billion yuan in Series E financing, which was continued by Haitong Innovation, SDIC Venture Capital and Fosun Pharma. Xiangxue Pharmaceutical announced the completion of the 2 billion yuan F round of financing, which was led by Haitong Innovation, SDIC Venture Capital, Fosun Pharma, Sequoia Capital China and Huaying Capital. Xiangxue Pharmaceutical received 3 billion yuan in Series G financing, and many well-known investment institutions participated, including Haitong Innovation, SDIC Venture Capital, Fosun Pharma, Sequoia Capital China and Huaying Capital. It is reported that Xiangxue Pharmaceutical plans to raise funds through internal financing to support the company's business development and research and development projects, and it has also been officially launched. Guangzhou Xiangxue Pharmaceutical Co., Ltd., headquartered in Science City, Guangzhou Economic and Technological Development Zone, is a modern high-tech pharmaceutical enterprise focusing on Chinese patent medicine pharmacy and research and development, integrating western medicine pharmacy, biomedical engineering and standardized cultivation of medicinal materials.